- Home
- CELC vs HTGC Comparison
CELC vs HTGC Comparison
Compare CELC & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELC | HTGC |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CELC | HTGC |
|---|---|---|
| Price | $104.77 | $18.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $100.13 | $21.13 |
| AVG Volume (30 Days) | 863.3K | ★ 1.1M |
| Earning Date | 11-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 9.98% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | N/A | ★ $516,847,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | N/A | $9.64 |
| P/E Ratio | ★ N/A | $10.75 |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $7.58 | $15.65 |
| 52 Week High | $112.64 | $22.04 |
Technical Indicators
Market Signals| Indicator | CELC | HTGC |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 53.18 |
| Support Level | $98.50 | $18.69 |
| Resistance Level | $103.09 | $19.03 |
| Average True Range (ATR) | 3.54 | 0.23 |
| MACD | -0.65 | -0.02 |
| Stochastic Oscillator | 78.85 | 45.14 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.